These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Dres M; Hausfater P; Foissac F; Bernard M; Joly LM; Sebbane M; Philippon AL; Gil-Jardiné C; Schmidt J; Maignan M; Treluyer JM; Roche N Int J Chron Obstruct Pulmon Dis; 2017; 12():1047-1056. PubMed ID: 28408815 [TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19. Lo Sasso B; Gambino CM; Scichilone N; Giglio RV; Bivona G; Scazzone C; Muratore R; Milano S; Barbagallo M; Agnello L; Ciaccio M Lab Med; 2021 Sep; 52(5):493-498. PubMed ID: 33928380 [TBL] [Abstract][Full Text] [Related]
9. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study. van Oers JAH; Kluiters Y; Bons JAP; de Jongh M; Pouwels S; Ramnarain D; de Lange DW; de Grooth HJ; Girbes ARJ J Crit Care; 2021 Dec; 66():173-180. PubMed ID: 34340901 [TBL] [Abstract][Full Text] [Related]
10. Mid-regional proadrenomedullin, C-terminal proendothelin-1 values, and disease course are not different in critically ill SARS-CoV-2 pneumonia patients with obesity. van Oers JAH; Pouwels S; Ramnarain D; Kluiters Y; Bons JAP; de Lange DW; de Grooth HJ; Girbes ARJ Int J Obes (Lond); 2022 Oct; 46(10):1801-1807. PubMed ID: 35840771 [TBL] [Abstract][Full Text] [Related]
11. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial. Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P; Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637 [TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients? Zaninotto M; Mion MM; Marchioro L; Padoan A; Plebani M Clin Chim Acta; 2021 Dec; 523():185-190. PubMed ID: 34555411 [TBL] [Abstract][Full Text] [Related]
14. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sozio E; Tascini C; Fabris M; D'Aurizio F; De Carlo C; Graziano E; Bassi F; Sbrana F; Ripoli A; Pagotto A; Giacinta A; Gerussi V; Visentini D; De Stefanis P; Merelli M; Saeed K; Curcio F Sci Rep; 2021 Mar; 11(1):5121. PubMed ID: 33664308 [TBL] [Abstract][Full Text] [Related]
15. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Sozio E; Moore NA; Fabris M; Ripoli A; Rumbolo F; Minieri M; Boverio R; Rodríguez Mulero MD; Lainez-Martinez S; Martínez Martínez M; Calvo D; Gregoriano C; Williams R; Brazzi L; Terrinoni A; Callegari T; Hernández Olivo M; Esteban-Torrella P; Calcerrada I; Bernasconi L; Kidd SP; Sbrana F; Miguens I; Gordon K; Visentini D; Legramante JM; Bassi F; Cortes N; Montrucchio G; Di Lecce VN; Lauritano EC; García de Guadiana-Romualdo L; González Del Castillo J; Bernal-Morell E; Andaluz-Ojeda D; Schuetz P; Curcio F; Tascini C; Saeed K Respir Res; 2022 Aug; 23(1):221. PubMed ID: 36031619 [TBL] [Abstract][Full Text] [Related]
16. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Saeed K; Wilson DC; Bloos F; Schuetz P; van der Does Y; Melander O; Hausfater P; Legramante JM; Claessens YE; Amin D; Rosenqvist M; White G; Mueller B; Limper M; Callejo CC; Brandi A; Macchi MA; Cortes N; Kutz A; Patka P; Yañez MC; Bernardini S; Beau N; Dryden M; van Gorp ECM; Minieri M; Chan L; Rood PPM; Del Castillo JG Crit Care; 2019 Feb; 23(1):40. PubMed ID: 30736862 [TBL] [Abstract][Full Text] [Related]
17. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy. Falkentoft AC; Rørth R; Iversen K; Høfsten DE; Kelbæk H; Holmvang L; Frydland M; Schoos MM; Helqvist S; Axelsson A; Clemmensen P; Jørgensen E; Saunamäki K; Tilsted HH; Pedersen F; Torp-Pedersen C; Kofoed KF; Goetze JP; Engstrøm T; Køber L J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776961 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Mid-Region Proadrenomedullin and In Vitro Interferon Gamma Production for In-Hospital Mortality in Patients with COVID-19 Pneumonia and Respiratory Failure: An Observational Prospective Study. Mangioni D; Oggioni M; Chatenoud L; Liparoti A; Uceda Renteria S; Alagna L; Biscarini S; Bolis M; Di Modugno A; Mussa M; Renisi G; Ungaro R; Muscatello A; Gori A; Ceriotti F; Bandera A Viruses; 2022 Jul; 14(8):. PubMed ID: 36016305 [TBL] [Abstract][Full Text] [Related]
19. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study. Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681 [TBL] [Abstract][Full Text] [Related]
20. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH. Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]